(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of 18.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Rigel Pharmaceuticals's revenue in 2026 is $276,785,000.On average, 7 Wall Street analysts forecast RIGL's revenue for 2026 to be $5,825,315,588, with the lowest RIGL revenue forecast at $5,383,163,208, and the highest RIGL revenue forecast at $6,242,997,347. On average, 7 Wall Street analysts forecast RIGL's revenue for 2027 to be $7,103,765,481, with the lowest RIGL revenue forecast at $6,040,881,219, and the highest RIGL revenue forecast at $7,990,685,423.
In 2028, RIGL is forecast to generate $8,675,302,439 in revenue, with the lowest revenue forecast at $7,330,352,231 and the highest revenue forecast at $9,479,470,584.